| 董元元,樊恭春,熊艳林,尹义平,周 琴,朱建勇.沙丁胺醇联合福多司坦治疗慢性阻塞性肺疾病稳定期的疗效及对患者血清IL-6、TNF-α、hs-CRP水平的影响[J].,2019,19(17):3389-3392 |
| 沙丁胺醇联合福多司坦治疗慢性阻塞性肺疾病稳定期的疗效及对患者血清IL-6、TNF-α、hs-CRP水平的影响 |
| Curative Efficacy of Salbutamol Combined with Fordostatin in the Treatment of Chronic Obstructive Pulmonary Disease at the Stable Stage and Its Effects on the Serum IL-6, TNF-α, and hs-CRP Levels |
| 投稿时间：2019-03-03 修订日期：2019-03-27 |
| DOI：10.13241/j.cnki.pmb.2019.17.040 |
| 中文关键词: 沙丁胺醇 福多司坦 慢性阻塞性肺疾病 白细胞介素-6 肿瘤坏死因子?琢 超敏c反应蛋白 |
| 英文关键词: Salbutamol Fordostein Chronic obstructive pulmonary disease Interleukin-6 Tumor necrosis factor Hypersensitive c-reactive protein |
| 基金项目:湖北省科技计划项目(2013029) |
|
| 摘要点击次数: 769 |
| 全文下载次数: 507 |
| 中文摘要: |
| 摘要 目的：探讨沙丁胺醇联合福多司坦治疗慢性阻塞性肺疾病稳定期的临床疗效及对患者血清白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)、超敏c反应蛋白(hs-CRP)水平的影响。方法：选择2016年1月到2017年1月我院接诊的稳定期慢性阻塞性肺病患者100例作为研究对象，按照随机数表法分为观察组(n=51)和对照组(n=49)。对照组使用沙丁胺醇治疗，观察组采用沙丁胺醇联合福多司坦治疗。比较两组治疗后的疗效、治疗前后血清IL-6、TNF-α、hs-CRP、肺功能的变化及不良反应的发生情况。结果：治疗后，观察组临床疗效总有效率(94.12%)显著高于对照组(75.51%，P＜0.05)。两组患者治疗后血清IL-6、TNF-α、hs-CRP水平均治疗前均明显下降，且观察组患者血清IL-6、TNF-α、hs-CRP水平均明显低于对照组(P＜0.05)；两组治疗后各第1秒用力呼气容积 (FEV1)、用力肺活量(FVC)、最大呼气流量(PEF)较治疗前均显著升高(P＜0.05)，且观察组FEV1、FVC、PEF均明显高于对照组(P＜0.05)；两组患者不良反应总发生率分别19.61%、38.78%，观察组显著低于对照组(P<0.05)。结论：沙丁胺醇联合福多司坦治疗慢性阻塞性肺疾病稳定期的临床疗效和安全性均显著优于单用沙丁胺醇治疗，可能与其有效改善患者血清IL-6、TNF-α、hs-CRP水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the curative efficacy of Salbutamol combined with fordostatin in the treatment of chronic obstructive pulmonary disease(COPD) at stable stage and its effects on the serum interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), hypersensitive c-reactive protein (hs-CRP). Methods: 100 patients with COPD at stable stage who were treated in our hospital from January 2016 to January 2017 were selected as the subjects, they were divided into the observation group (n=51) and the control group (n=49) according to the randomized table. The control group was treated with salbutamol, and the observation group was treated with salbutamol combined with fordostatin. The efficacy, changes of serum IL-6, TNF-α, hs-CRP, pulmonary function before and after treatment and the incidence of adverse reactions were compared between the two groups. Results: After treatment, the total effective rate (94.12%) in the observation group was significantly higher than that in the control group (75.51%, P<0.05). The serum IL-6, TNF-α, and hs-crp levels in both groups were significantly decreased after treatment, and serum il-6, TNF-α, and hs-CRP levels in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the forced expiratory volume (FEV1), forced vital capacity (FVC), and maximum expiratory flow (PEF) in both groups were significantly increased (P<0.05), and the FEV1, FVC, and PEF in the observation group were significantly higher than those in the control group (P<0.05). The total incidence of adverse reactions in the two groups was 19.61% and 38.78%, respectively, which was significantly lower in the observation group than that of the control group (P<0.05). Conclusion: The clinical efficacy and safety of salbutamol combined with fodostam in the treatment of COPD at stable stage is significantly better than that of salbutamol alone, which may be related to the effective improvement of serum IL-6, TNF-α, hs-CRP levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
